Zacks Research Has Optimistic Outlook of RDY Q2 Earnings

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Zacks Research increased their Q2 2027 earnings per share (EPS) estimates for Dr. Reddy’s Laboratories in a research note issued to investors on Wednesday, October 16th. Zacks Research analyst R. Department now expects that the company will earn $0.78 per share for the quarter, up from their prior estimate of $0.77. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $4.11 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ FY2027 earnings at $3.13 EPS.

Separately, Barclays boosted their price objective on shares of Dr. Reddy’s Laboratories from $81.00 to $87.00 and gave the company an “overweight” rating in a research report on Tuesday, July 30th.

Dr. Reddy’s Laboratories Stock Up 0.8 %

Shares of RDY stock opened at $79.80 on Friday. The company has a current ratio of 2.55, a quick ratio of 1.90 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories has a 12 month low of $63.72 and a 12 month high of $84.46. The stock has a market cap of $13.32 billion, a P/E ratio of 19.80, a P/E/G ratio of 1.73 and a beta of 0.55. The company has a 50 day simple moving average of $80.46 and a two-hundred day simple moving average of $76.31.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings results on Saturday, July 27th. The company reported $1.00 EPS for the quarter, missing the consensus estimate of $1.10 by ($0.10). The business had revenue of $919.80 million for the quarter, compared to analysts’ expectations of $861.68 million. Dr. Reddy’s Laboratories had a net margin of 19.28% and a return on equity of 20.32%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. GAMMA Investing LLC raised its stake in Dr. Reddy’s Laboratories by 54.7% during the 1st quarter. GAMMA Investing LLC now owns 721 shares of the company’s stock worth $53,000 after acquiring an additional 255 shares during the period. Contravisory Investment Management Inc. bought a new position in Dr. Reddy’s Laboratories in the 1st quarter worth $189,000. CWM LLC increased its stake in Dr. Reddy’s Laboratories by 18.9% in the 1st quarter. CWM LLC now owns 2,584 shares of the company’s stock worth $190,000 after buying an additional 410 shares in the last quarter. Wealthstream Advisors Inc. bought a new stake in Dr. Reddy’s Laboratories during the second quarter valued at about $203,000. Finally, Legacy Capital Group California Inc. purchased a new position in shares of Dr. Reddy’s Laboratories in the second quarter valued at about $204,000. 14.02% of the stock is owned by hedge funds and other institutional investors.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.